Market Summary
USD234.57-0.33
Market Closed-0.14%
AMGN Stock Price
AMGN RSI Chart
AMGN Valuation
AMGN Price/Sales (Trailing)
AMGN Profitability
AMGN Fundamentals
AMGN Revenue
AMGN Earnings
Price Action
52 Week Range
221.77294.64
(Low)(High)
Last 7 days
2.8%
Last 30 days
-2.7%
Last 90 days
-11.7%
Trailing 12 Months
3.8%
AMGN Financial Health
AMGN Investor Care
Peers (Alternatives to Amgen)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 125.3B | 26.3B | -2.75% | 3.76% | 19.12 | 4.76 | 1.32% | 11.18% |
GILD | 99.6B | 27.3B | -8.96% | 41.01% | 21.68 | 3.65 | -0.09% | -26.23% |
MRNA | 58.4B | 19.3B | -12.76% | 1.00% | 6.99 | 3.03 | 4.29% | -31.47% |
BIIB | 38.3B | 10.2B | -9.67% | 32.94% | 12.57 | 3.76 | -7.36% | 95.80% |
| MID-CAP | ||||||||
NBIX | 9.1B | 1.5B | -9.09% | 3.35% | 58.87 | 6.11 | 31.34% | 72.43% |
DNLI | 3.2B | 108.5M | -21.10% | -19.55% | -9.78 | 29.38 | 122.90% | -12.19% |
BEAM | 2.5B | 60.9M | -18.47% | -36.46% | -8.76 | 41.55 | 17.51% | 22.00% |
BBIO | 2.1B | 107.9M | 22.95% | 67.45% | -4.29 | 19.27 | 54.84% | 17.36% |
| SMALL-CAP | ||||||||
RCUS | 1.2B | 112.0M | -14.86% | -46.41% | -4.63 | 11.04 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -22.18% | 24.65% | -7.11 | 158.97 | 131.81% | -45.39% |
FATE | 541.9M | 96.3M | -12.99% | -82.24% | -1.92 | 5.63 | 72.44% | -32.79% |
NVAX | 513.7M | 2.0B | -39.67% | -92.01% | -0.78 | 0.26 | 72.89% | 62.27% |
SGMO | 355.3M | 111.3M | -30.55% | -58.78% | -1.85 | 3.19 | 0.54% | -7.86% |
VXRT | 101.4M | 159.0K | -16.47% | -82.96% | -0.97 | 637.62 | -86.46% | -64.56% |
IBIO | 25.1M | - | 94.03% | -77.12% | -0.31 | 3.21 | 0.51% | -185.61% |
Financials for Amgen
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 0.0% | 26,323 | 26,330 | 26,384 | 26,316 | 25,979 |
| S&GA Expenses | 2.8% | 5,414 | 5,267 | 5,285 | 5,342 | 5,368 |
| Costs and Expenses | 0.4% | 16,757 | 16,690 | 17,026 | 18,306 | 18,340 |
| EBITDA | -2.0% | 12,169 | 12,413 | 12,117 | 11,124 | - |
| EBITDA Margin | -1.9% | 0.46* | 0.47* | 0.46* | 0.42* | - |
| Earnings Before Taxes | -5.0% | 7,346 | 7,729 | 7,492 | 6,519 | 6,701 |
| EBT Margin | -4.9% | 0.28* | 0.29* | 0.28* | 0.25* | - |
| Interest Expenses | 6.0% | 1,406 | 1,326 | 1,254 | 1,207 | 1,197 |
| Net Income | -4.1% | 6,552 | 6,835 | 6,576 | 5,723 | 5,893 |
| Net Income Margin | -4.1% | 0.25* | 0.26* | 0.25* | 0.22* | - |
| Free Cahsflow | -2.4% | 8,785 | 8,997 | 8,355 | 8,417 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 2.2% | 65,121 | 63,700 | 59,294 | 59,196 | 61,165 |
| Current Assets | -7.8% | 22,186 | 24,062 | 19,322 | 18,520 | 19,385 |
| Cash Equivalents | -19.7% | 7,629 | 9,502 | 5,203 | 6,528 | 7,989 |
| Inventory | 3.6% | 4,930 | 4,757 | 4,554 | 4,411 | 4,086 |
| Net PPE | 4.6% | 5,427 | 5,188 | 5,158 | 5,142 | 5,184 |
| Goodwill | 4.6% | 15,529 | 14,845 | 14,865 | 14,897 | 14,890 |
| Current Liabilities | 9.5% | 15,687 | 14,331 | 12,618 | 12,886 | 12,184 |
| Long Term Debt | - | 33,309 | - | - | - | - |
| LT Debt, Current | 3.1% | 1,591 | 1,543 | 817 | 844 | 87.00 |
| LT Debt, Non Current | 0.5% | 37,354 | 37,161 | 35,705 | 36,010 | 33,222 |
| Shareholder's Equity | 0.2% | 3,661 | 3,653 | 2,419 | 916 | 6,700 |
| Retained Earnings | -2.0% | -28,622 | -28,066 | -28,252 | -29,568 | -24,600 |
| Shares Outstanding | 0.1% | 534 | 534 | 535 | 534 | 558 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | -1.6% | 9,721 | 9,880 | 9,320 | 9,321 | 9,261 |
| Share Based Compensation | 17.6% | 401 | 341 | - | - | - |
| Cashflow From Investing | -115.8% | -6,044 | -2,801 | -2,461 | 941 | 733 |
| Cashflow From Financing | 57.7% | -4,037 | -9,546 | -8,286 | -9,846 | -8,271 |
| Dividend Payments | 1.2% | 4,196 | 4,146 | 4,107 | 4,077 | 4,013 |
| Buy Backs | -18.5% | 6,360 | 7,803 | 8,872 | 10,414 | 4,975 |
Risks for AMGN
What is the probability of a big loss on AMGN?
17.3%
Probability that Amgen stock will be more than 20% underwater in next one year
0%
Probability that Amgen stock will be more than 30% underwater in next one year.
0%
Probability that Amgen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does AMGN drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Amgen was unfortunately bought at previous high price.
Drawdowns
Returns for AMGN
Cumulative Returns on AMGN
12.8%
10-Year Cumulative Returns
10.4%
7-Year Cumulative Returns
7.7%
5-Year Cumulative Returns
8.3%
3-Year Cumulative Returns
What are the long-term rolling returns for AMGN?
FIve years rolling returns for Amgen.
Annualized Returns
Which funds bought or sold AMGN recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | reduced | -13.27 | 100,348 | 9,602,350 | 0.27% |
2023-03-13 | Claro Advisors LLC | added | 15.86 | 85,755 | 427,755 | 0.14% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -0.89 | 41,664,100 | 310,811,000 | 0.34% |
2023-03-10 | MATHER GROUP, LLC. | reduced | -4.99 | 104,685 | 1,079,680 | 0.02% |
2023-03-08 | Capital Asset Advisory Services LLC | added | 0.06 | 60,848 | 407,848 | 0.03% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | reduced | -0.02 | 498,674 | 3,523,670 | 0.55% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | added | 0.49 | 397,586 | 2,718,590 | 0.17% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -2.67 | 8,583,000 | 72,555,000 | 0.36% |
2023-03-03 | TIAA, FSB | reduced | -4.78 | 2,393,810 | 24,249,800 | 0.10% |
2023-03-02 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | new | - | 22,157,100 | 22,157,100 | 0.27% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Amgen News
Schedule 13G FIlings of Amgen
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 9.01% | 48,065,139 | SC 13G/A | |
| Feb 07, 2023 | blackrock inc. | 9.1% | 48,513,079 | SC 13G/A | |
| Feb 06, 2023 | state street corp | 5.58% | 29,760,088 | SC 13G/A | |
| Feb 11, 2022 | capital research global investors | 3.9% | 22,157,906 | SC 13G/A | |
| Feb 10, 2022 | state street corp | 5.37% | 30,221,708 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 8.28% | 46,661,009 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 8.9% | 50,046,345 | SC 13G/A | |
| Feb 16, 2021 | capital research global investors | 5.5% | 31,762,327 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 8.11% | 47,227,229 | SC 13G/A | |
| Feb 05, 2021 | state street corp | 5.17% | 30,113,284 | SC 13G |
AMGN Fair Value
Amgen fair value in different scenarios
The table shows the Fair Value estimates for Amgen for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 109.17 -53.46% | 132.66 -43.45% | 169.25 -27.85% | 258.30 10.12% | 304.31 29.73% |
| Current Inflation | 100.97 -56.96% | 121.19 -48.34% | 151.99 -35.20% | 226.05 -3.63% | 264.21 12.64% |
| Very High Inflation | 90.72 -61.32% | 107.13 -54.33% | 131.32 -44.02% | 188.71 -19.55% | 218.22 -6.97% |
Historical Amgen Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Amgen
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 09, 2023 | 8-K | Current Report | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for AMGN
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-06 | Griffith Peter H. | acquired | - | - | 7,753 | evp & cfo |
2023-03-06 | Louie Linda H. | acquired | - | - | 387 | vp, finance & cao |
2023-03-06 | Gordon Murdo | acquired | - | - | 7,947 | evp global commercial ops |
2023-03-06 | Grygiel Nancy A. | acquired | - | - | 968 | svp & cco |
2023-03-06 | Graham Jonathan P | acquired | - | - | 7,560 | evp, gen. counsel & secy. |
2023-03-06 | Santos Esteban | acquired | - | - | 7,753 | evp, operations |
2023-03-06 | REESE DAVID M | acquired | - | - | 7,947 | evp, research and development |
2023-03-06 | Khosla Rachna | acquired | - | - | 687 | svp, business development |
2023-03-06 | Bradway Robert A | acquired | - | - | 27,915 | chairman, ceo and president |
2023-03-06 | Miller Derek | acquired | - | - | 920 | svp, human resources |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
AMGN Income Statement
2022-12-31Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Revenues: | |||
| Total revenues | $ 26,323 | $ 25,979 | $ 25,424 |
| Operating expenses: | |||
| Cost of sales | 6,406 | 6,454 | 6,159 |
| Research and development | 4,434 | 4,819 | 4,207 |
| Acquired in-process research and development | 0 | 1,505 | 0 |
| Selling, general and administrative | 5,414 | 5,368 | 5,730 |
| Other | 503 | 194 | 189 |
| Total operating expenses | 16,757 | 18,340 | 16,285 |
| Operating income | 9,566 | 7,639 | 9,139 |
| Interest expense, net | (1,406) | (1,197) | (1,262) |
| Other (expense) income, net | (814) | 259 | 256 |
| Income before income taxes | 7,346 | 6,701 | 8,133 |
| Provision for income taxes | 794 | 808 | 869 |
| Net income | $ 6,552 | $ 5,893 | $ 7,264 |
| Earnings per share: | |||
| Basic (in usd per share) | $ 12.18 | $ 10.34 | $ 12.40 |
| Diluted (in usd per share) | $ 12.11 | $ 10.28 | $ 12.31 |
| Shares used in the calculation of earnings per share: | |||
| Basic (in shares) | 538 | 570 | 586 |
| Diluted (in shares) | 541 | 573 | 590 |
| Product sales | |||
| Revenues: | |||
| Total revenues | $ 24,801 | $ 24,297 | $ 24,240 |
| Other revenues | |||
| Revenues: | |||
| Total revenues | $ 1,522 | $ 1,682 | $ 1,184 |
AMGN Balance Sheet
2022-12-31Consolidated Balance Sheets - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 7,629 | $ 7,989 |
| Marketable securities | 1,676 | 48 |
| Trade receivables, net | 5,563 | 4,895 |
| Inventories | 4,930 | 4,086 |
| Other current assets | 2,388 | 2,367 |
| Total current assets | 22,186 | 19,385 |
| Property, plant and equipment, net | 5,427 | 5,184 |
| Intangible assets, net | 16,080 | 15,182 |
| Goodwill | 15,529 | 14,890 |
| Other noncurrent assets | 5,899 | 6,524 |
| Total assets | 65,121 | 61,165 |
| Current liabilities: | ||
| Accounts payable | 1,572 | 1,366 |
| Accrued liabilities | 12,524 | 10,731 |
| Current portion of long-term debt | 1,591 | 87 |
| Total current liabilities | 15,687 | 12,184 |
| Long-term debt | 37,354 | 33,222 |
| Long-term tax liabilities | 5,757 | 6,594 |
| Other noncurrent liabilities | 2,662 | 2,465 |
| Contingencies and commitments | ||
| Stockholders’ equity: | ||
| Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding—534.0 shares in 2022 and 558.3 shares in 2021 | 32,514 | 32,096 |
| Accumulated deficit | (28,622) | (24,600) |
| Accumulated other comprehensive loss | (231) | (796) |
| Total stockholders’ equity | 3,661 | 6,700 |
| Total liabilities and stockholders’ equity | $ 65,121 | $ 61,165 |